Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6130675 | 0.80 | CA1 (0.39) | — | |
| SCHEMBL6433059 | 0.79 | TSHR (0.43) | TSHRMAPK1MEN1KMT2AUSP2 | |
| SCHEMBL21855420 | 0.75 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AUSP2 | |
| SCHEMBL13028968 | 0.75 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AUSP2 | |
| SCHEMBL1219820 | 0.75 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AUSP2 | |
| SCHEMBL28098697 | 0.75 | MEN1 (0.50) | TSHRMAPK1MEN1KMT2AUSP2 | |
| SCHEMBL17342799 | 0.74 | TSHR (0.43) | TSHRMAPK1MEN1KMT2A | |
| SCHEMBL10366419 | 0.74 | TSHR (0.38) | TSHRMAPK1MEN1KMT2AUSP2 | |
| SCHEMBL9559516 | 0.74 | TSHR (0.38) | TSHRMAPK1MEN1KMT2AUSP2 | |
| SCHEMBL9446799 | 0.74 | ALDH1A1 (0.48) | TSHRMAPK1MEN1KMT2AUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050064468-A1 | concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports | IBC ADVANCED TECHNOLOGIES, INC. | 2005-03-24 | — | — | US | disclosed |
| EP-1453602-A4 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECH INC (US) | 2005-01-12 | — | — | EP | disclosed |
| EP-1453602-A2 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2004-09-08 | — | — | EP | disclosed |
| WO-2002092766-A2 | COMPOSITIONS AND METHODS FOR SEPARATING HETEROCYCLIC AROMATIC AMINE BASES, NUCLEOSIDES, NUCLEOTIDES, AND NUCLEOTIDE SEQUENCES | IBC ADVANCED TECHNOLOGIES, INC. (US) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050064468-A1 | concentration, removing or separation of nucleotide bases or nucleotide sequences containing bases from solid supports | NUDT1, PCNA, NSUN2 | TSHR 2665/4885MAPK1 3243/4885MEN1 2474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.